Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Researchers from the Tel Aviv University successfully engineer the world's first 3D human spinal cord tissue transplant
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Subscribe To Our Newsletter & Stay Updated
